FROM THE ANALYST'S COUCH

The failure to fail smartly

Global Regulatory Affairs and Safety, Amgen, Thousand Oaks, CA, USA.

Search for this author in:

National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, USA.

Search for this author in:

The National Academies of Sciences, Engineering, and Medicine, Washington, DC, USA.

Search for this author in:

Critical Path Institute, Tucson, AZ, USA.

Search for this author in:

Tufts Center for the Study of Drug Development, Tufts University, Boston, MA, USA.

Search for this author in:

Verily Life Sciences, Mountain View, CA, USA.

Search for this author in:

Cygnal Therapeutics, Cambridge, MA, USA.
Contact

Search for this author in:

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Acknowledgements

The authors thank the staff of the National Academies Forum on Drug Discovery, Development, and Translation, including C. Shore and A. Wagner Gee, for contributing to the development of the action collaborative and review of this manuscript. Additional thanks go to D. Bearss and J. Mendoza-Torres from the Research Center at the National Academies for providing research support. The authors also thank M.D. Mostats from Amgen for his insight and technical assistance on benchmarking data. They gratefully acknowledge leadership made by the collaborative participants (listed in the supplementary information) and input by the many experts who shared their experience and suggestions on how to improve drug development. Lastly, the authors thank the members of the Forum on Drug, Discovery, Development and Translation for their guidance on developing the action collaborative.

Disclaimer

The Improving the Drug Development Process through Examining Late-Stage Failures Action Collaborative is an ad hoc activity associated with the US National Academies’ Forum on Drug Discovery, Development, and Translation. It does not necessarily represent the views of any one organization, the Forum, or the National Academies and is not subjected to the review procedures of, nor is it a report or product of, the National Academies.

Supplementary Information

  1. Supplementary Box 1

Competing Financial Interests

S.G. is an employee of Amgen. R.C. is an employee of Verily Life Sciences. J.A.W. is an employee of Cygnal Therapeutics. C.P.A and J.A.W. are members of the FNIH Biomarkers Consortium executive committee. E.K., L.D.H. and J.A.D. declare no competing interests.

Nature Briefing

An essential round-up of science news, opinion and analysis, delivered to your inbox every weekday.